Madeleine Williams
Stock Analyst at Canaccord Genuity
(0.86)
# 4,046
Out of 5,073 analysts
95
Total ratings
31.4%
Success rate
-2.7%
Average return
Main Sectors:
Stocks Rated by Madeleine Williams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASX: CGS Cogstate Limited | Reiterated: Buy | $3.15 → $4.15 | $3.58 | +15.92% | 6 | Oct 12, 2026 | |
| ASX: CU6 Clarity Pharmaceuticals Ltd | Reiterated: Buy | $8.41 → $8.38 | $1.78 | +370.79% | 13 | Sep 16, 2026 | |
| ASX: NEU Neuren Pharmaceuticals Limited | Reiterated: Buy | $24.76 | $19.70 | +25.69% | 8 | Aug 29, 2026 | |
| ASX: CUV Clinuvel Pharmaceuticals Limited | Downgraded: Hold | $27.90 → $9.52 | $7.38 | +29.00% | 3 | Aug 27, 2026 | |
| ASX: MSB Mesoblast Limited | Reiterated: Buy | $3.56 | $1.86 | +91.40% | 7 | Aug 27, 2026 | |
| ASX: MYX Mayne Pharma Group Limited | Reiterated: Buy | $3.83 → $3.75 | $2.54 | +47.64% | 5 | Aug 27, 2026 | |
| ASX: EBR EBR Systems, Inc. | Reiterated: Buy | $2.27 → $1.91 | $0.15 | +1,217.24% | 12 | Aug 21, 2026 | |
| ASX: ATH Alterity Therapeutics Limited | Reiterated: Buy | $0.95 | $0.26 | +272.55% | 5 | Aug 13, 2026 | |
| ASX: M7T Mach7 Technologies Limited | Reiterated: Hold | $0.27 → $0.32 | $0.22 | +45.45% | 3 | Jul 30, 2026 | |
| ASX: BOT Botanix Pharmaceuticals Limited | Reiterated: Buy | $0.14 | $0.01 | +976.92% | 6 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $0.15 | $0.02 | +650.00% | 9 | Jul 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2.28 | $1.35 | +69.52% | 7 | Jul 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2.84 | $1.80 | +57.78% | 3 | Jun 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $180.82 → $168.62 | $184.83 | -8.77% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1.27 → $0.40 | $0.02 | +1,566.67% | 3 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27.33 → $27.41 | $14.52 | n/a | 2 | Oct 15, 2025 |
Cogstate Limited
Oct 12, 2026
Reiterated: Buy
Price Target: $3.15 → $4.15
Current: $3.58
Upside: +15.92%
Clarity Pharmaceuticals Ltd
Sep 16, 2026
Reiterated: Buy
Price Target: $8.41 → $8.38
Current: $1.78
Upside: +370.79%
Neuren Pharmaceuticals Limited
Aug 29, 2026
Reiterated: Buy
Price Target: $24.76
Current: $19.70
Upside: +25.69%
Clinuvel Pharmaceuticals Limited
Aug 27, 2026
Downgraded: Hold
Price Target: $27.90 → $9.52
Current: $7.38
Upside: +29.00%
Mesoblast Limited
Aug 27, 2026
Reiterated: Buy
Price Target: $3.56
Current: $1.86
Upside: +91.40%
Mayne Pharma Group Limited
Aug 27, 2026
Reiterated: Buy
Price Target: $3.83 → $3.75
Current: $2.54
Upside: +47.64%
EBR Systems, Inc.
Aug 21, 2026
Reiterated: Buy
Price Target: $2.27 → $1.91
Current: $0.15
Upside: +1,217.24%
Alterity Therapeutics Limited
Aug 13, 2026
Reiterated: Buy
Price Target: $0.95
Current: $0.26
Upside: +272.55%
Mach7 Technologies Limited
Jul 30, 2026
Reiterated: Hold
Price Target: $0.27 → $0.32
Current: $0.22
Upside: +45.45%
Botanix Pharmaceuticals Limited
Jul 29, 2026
Reiterated: Buy
Price Target: $0.14
Current: $0.01
Upside: +976.92%
Jul 8, 2026
Reiterated: Buy
Price Target: $0.15
Current: $0.02
Upside: +650.00%
Jul 4, 2026
Reiterated: Buy
Price Target: $2.28
Current: $1.35
Upside: +69.52%
Jun 6, 2026
Reiterated: Buy
Price Target: $2.84
Current: $1.80
Upside: +57.78%
May 12, 2026
Reiterated: Buy
Price Target: $180.82 → $168.62
Current: $184.83
Upside: -8.77%
Mar 13, 2026
Reiterated: Buy
Price Target: $1.27 → $0.40
Current: $0.02
Upside: +1,566.67%
Oct 15, 2025
Reiterated: Buy
Price Target: $27.33 → $27.41
Current: $14.52
Upside: n/a